

Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol in Statin-Intolerant Patients

JAMA - Journal of the American Medical Association

308, 2497

DOI: [10.1001/jama.2012.25790](https://doi.org/10.1001/jama.2012.25790)

Citation Report

#	ARTICLE	IF	CITATIONS
1	PCSK9, a novel target for lowering LDL cholesterol: promise and progress. <i>Clinical Lipidology</i> , 2012, 7, 611-615.	0.4	2
2	PCSK9 inhibition and LDL cholesterol lowering: the biology of an attractive therapeutic target and critical review of the latest clinical trials. <i>Clinical Lipidology</i> , 2012, 7, 621-640.	0.4	16
3	Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics. <i>Current Atherosclerosis Reports</i> , 2013, 15, 310.	2.0	71
4	Novel pharmacotherapies of familial hyperlipidemia. , 2013, 139, 301-312.		2
5	Diagnosis and Management of Familial Dyslipoproteinemias. <i>Current Cardiology Reports</i> , 2013, 15, 371.	1.3	11
6	Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: A clinical update. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013, 23, 799-807.	1.1	111
7	New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 559-567.	1.3	133
8	PCSK9 : une nouvelle cible pour le traitement de l'hypercholestérolémie. <i>Medecine Des Maladies Metaboliques</i> , 2013, 7, 413-420.	0.1	1
9	STOMPing forward: Statins, muscle complaints and CK. <i>Atherosclerosis</i> , 2013, 230, 256-257.	0.4	6
10	The next generation of novel low-density lipoprotein cholesterol-lowering agents: Proprotein convertase subtilisin/kexin 9 inhibitors. <i>Pharmacological Research</i> , 2013, 73, 27-34.	3.1	17
11	Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1401-1408.	1.2	241
12	New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. <i>European Heart Journal</i> , 2013, 34, 1783-1789.	1.0	90
13	Antibodies against PCSK9—a new era of therapy. <i>Nature Reviews Cardiology</i> , 2013, 10, 1-1.	6.1	13
14	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Working Group Consensus Update. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1553-1568.	0.8	153
15	New LDL-Cholesterol Lowering Therapies: Pharmacology, Clinical Trials, and Relevance to Acute Coronary Syndromes. <i>Clinical Therapeutics</i> , 2013, 35, 1082-1098.	1.1	134
16	Cardiovascular risk and lipid management beyond statin therapy: the potential role of omega-3 polyunsaturated fatty acid ethyl esters. <i>Clinical Lipidology</i> , 2013, 8, 329-344.	0.4	5
17	Evolution and Emergence of Therapeutic Monoclonal Antibodies. <i>Circulation</i> , 2013, 127, 2222-2230.	1.6	85
18	Summary of the Clinical Studies Reported in the Annual Scientific Sessions of the American Heart Association (Los Angeles, CA, USA, november 3-7, 2012). <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 55.e1-55.e11.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction. <i>Journal of Clinical Lipidology</i> , 2013, 7, S11-S15.	0.6	15
20	The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway. <i>Atherosclerosis</i> , 2013, 228, 18-28.	0.4	119
21	Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (Los Angeles, California, Estados Unidos, 3-7 de noviembre de 2012). <i>Revista Espanola De Cardiologia</i> , 2013, 66, 55.e1-55.e11.	0.6	17
22	Low-Density Lipoprotein Lowering in 2013 by Nonstatin Agents. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 199-210.	1.0	1
23	PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics. <i>Current Cardiology Reports</i> , 2013, 15, 345.	1.3	33
24	PCSK9 "an exciting target for reducing LDL-cholesterol levels. <i>Nature Reviews Endocrinology</i> , 2013, 9, 76-78.	4.3	10
25	Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: Hepatic and extra hepatic functions (ç→9ăžâ%è>ç™1/2è1/2-æé...¶â€”æž`è%æ°¶èç'è<ç™1/2é...¶Ki 391-405.		
26	Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum. <i>Journal of Clinical Lipidology</i> , 2013, 7, 217-221.	0.6	28
27	Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia. <i>Circulation</i> , 2013, 128, 2113-2120.	1.6	296
28	Evaluation of Proprotein Convertase Subtilisin/Kexin Type 9: Focus on Potential Clinical and Therapeutic Implications for Low-Density Lipoprotein Cholesterol Lowering. <i>Pharmacotherapy</i> , 2013, 33, 447-460.	1.2	5
29	FoxO3 Transcription Factor and Sirt6 Deacetylase Regulate Low Density Lipoprotein (LDL)-cholesterol Homeostasis via Control of the Proprotein Convertase Subtilisin/Kexin Type 9 (Pcsk9) Gene Expression. <i>Journal of Biological Chemistry</i> , 2013, 288, 29252-29259.	1.6	144
31	The discovery of PCSK9 inhibitors: A tale of creativity and multifaceted translational research. <i>Global Cardiology Science & Practice</i> , 2013, 2013, 39.	0.3	12
32	The promises of PCSK9 inhibition. <i>Current Opinion in Lipidology</i> , 2013, 24, 307-312.	1.2	17
33	Update on the detection and treatment of atherogenic low-density lipoproteins. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2013, 20, 140-147.	1.2	14
34	Therapy and clinical trials. <i>Current Opinion in Lipidology</i> , 2013, 24, 281-282.	1.2	1
35	Winner by points? " LDL cholesterol as a target for therapeutic intervention. <i>Current Opinion in Lipidology</i> , 2013, 24, 277-278.	1.2	0
36	PCSK9 inhibitors. <i>Current Opinion in Lipidology</i> , 2013, 24, 251-258.	1.2	39
37	The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. <i>Drug Design, Development and Therapy</i> , 2013, 7, 1135.	2.0	40

#	ARTICLE	IF	CITATIONS
38	New therapies to reduce low-density lipoprotein cholesterol. <i>Current Opinion in Cardiology</i> , 2013, 28, 452-457.	0.8	22
39	A potential role for monoclonal antibodies in clinical lipidology. <i>Current Opinion in Lipidology</i> , 2013, 24, 457-458.	1.2	0
40	Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1411-1423.	1.9	19
42	Human Genomics in Cardiovascular Medicine. <i>Circulation Journal</i> , 2013, 77, 876-885.	0.7	9
44	Reduction of LDL-C levels with AMG-145, a monoclonal antibody against PCSK9, in heterozygous familial hypercholesterolemia: the RUTHERFORD study. <i>Clinical Lipidology</i> , 2013, 8, 513-517.	0.4	0
45	Report of the American Heart Association (AHA) Scientific Sessions 2012, Los Angeles. <i>Circulation Journal</i> , 2013, 77, 35-40.	0.7	11
46	New Lipid-Lowering Drugs: The Potential for Further Reductions in Cardiovascular Events. <i>Cardiovascular Pharmacology: Open Access</i> , 2013, 2, .	0.1	0
48	The Newest Frontier in Cholesterol Management; PSCK 9. <i>Cardiovascular Pharmacology: Open Access</i> , 2014, 04, .	0.1	0
49	Beyond anti-PCSK9 therapies: the potential role of resistin inhibitors. <i>Nature Reviews Cardiology</i> , 2014, 11, 12-12.	6.1	6
50	Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. <i>European Heart Journal</i> , 2014, 35, 2249-2259.	1.0	115
51	Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia. <i>Medical Principles and Practice</i> , 2014, 23, 99-111.	1.1	49
52	Managing recalcitrant hypercholesterolemia in patients on current best standard of care: efficacy and safety of novel pharmacotherapies. <i>Clinical Lipidology</i> , 2014, 9, 221-233.	0.4	10
54	Antibodies to watch in 2014. <i>MAbs</i> , 2014, 6, 5-14.	2.6	90
55	Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 863-868.	1.4	20
56	Statin intolerance: more questions than answers. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 1-3.	1.3	7
57	Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. <i>Journal of Clinical Lipidology</i> , 2014, 8, 554-561.	0.6	128
58	New Therapies for Reducing Low-Density Lipoprotein Cholesterol. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 1007-1033.	1.2	35
59	Lipoprotein(a). <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 949-962.	1.2	27

#	ARTICLE	IF	CITATIONS
60	Combination Therapy with Statins. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 993-1006.	1.2	1
61	APOM and high-density lipoprotein cholesterol are associated with lung function and per cent emphysema. <i>European Respiratory Journal</i> , 2014, 43, 1003-1017.	3.1	37
62	Rationale and Design of <sc>LAPLACE</sc>â€²: A Phase 3, Randomized, Doubleâ€Blind, Placeboâ€and Ezetimibeâ€Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy. <i>Clinical Cardiology</i> , 2014, 37, 195-203.	0.7	12
63	Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century?. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1227-1239.	1.0	37
64	PCSK9 Antibodies for the Treatment of Hypercholesterolemia. <i>Nutrients</i> , 2014, 6, 5517-5533.	1.7	20
65	Efficacy and safety of ezetimibe plus atorvastatin therapy. <i>Clinical Lipidology</i> , 2014, 9, 441-470.	0.4	7
66	Antihyperlipidemic Therapies Targeting PCSK9. <i>Cardiology in Review</i> , 2014, 22, 140-146.	0.6	39
67	Use of monoclonal antibodies for proprotein convertase subtilisin kexin type 9 inhibition. <i>Current Opinion in Lipidology</i> , 2014, 25, 96-98.	1.2	1
68	Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1870.	3.8	422
69	GAUSS-2, RUTHERFORD-2, LAPLACE-2, DESCARTES, and TESLA Part B: PCSK9 inhibitors gain momentum. <i>Global Cardiology Science & Practice</i> , 2014, 2014, 49.	0.3	10
70	Ancestry and other genetic associations with plasma PCSK9 response to simvastatin. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 492-500.	0.7	13
72	Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2541-2548.	1.2	465
73	Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145). <i>Journal of the American College of Cardiology</i> , 2014, 63, 1278-1288.	1.2	316
74	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. <i>Journal of Clinical Lipidology</i> , 2014, 8, 148-172.	0.6	98
75	Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects. <i>Heart and Vessels</i> , 2014, 29, 129-141.	0.5	48
76	An Update on the Clinical Development of Proprotein Convertase Subtilisin Kexin 9 Inhibitors, Novel Therapeutic Agents for Lowering Lowâ€Density Lipoprotein Cholesterol. <i>Cardiovascular Therapeutics</i> , 2014, 32, 82-88.	1.1	16
77	Discovery of Innovative Therapeutics: Todayâ€™s Realities and Tomorrowâ€™s Vision. 2. Pharmaâ€™s Challenges and Their Commitment to Innovation. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 5525-5553.	2.9	43
78	Lipid, blood pressure and kidney update 2013. <i>International Urology and Nephrology</i> , 2014, 46, 947-961.	0.6	60

#	ARTICLE	IF	CITATIONS
80	Immunological aspects of atherosclerosis. <i>Seminars in Immunopathology</i> , 2014, 36, 73-91.	2.8	15
81	A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia. <i>New England Journal of Medicine</i> , 2014, 370, 1809-1819.	13.9	607
82	Advances in the Understanding of Plaque Composition and Treatment Options. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1604-1616.	1.2	45
83	The Severe Hypercholesterolemia Phenotype. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1935-1947.	1.2	153
84	Targeting LDL: Is lower better and is it safe?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 309-324.	2.2	27
85	PCSK9: From discovery to therapeutic applications. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 58-66.	0.7	83
86	Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. <i>Lancet, The</i> , 2014, 383, 60-68.	6.3	483
87	An Antibody against the C-Terminal Domain of PCSK9 Lowers LDL Cholesterol Levels In Vivo. <i>Journal of Molecular Biology</i> , 2014, 426, 843-852.	2.0	31
88	Secondary stroke prevention. <i>Lancet Neurology, The</i> , 2014, 13, 178-194.	4.9	227
89	Emerging drugs for hyperlipidaemia: an update. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 471-488.	1.0	5
90	Design and Rationale of the GAUSS-2 Study Trial: A Double-Blind, Ezetimibe-Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab (AMG 145) in Subjects With Hypercholesterolemia Who Are Intolerant of Statin Therapy. <i>Clinical Cardiology</i> , 2014, 37, 131-139.	0.7	25
91	Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs. <i>Current Atherosclerosis Reports</i> , 2014, 16, 439.	2.0	87
92	PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE. <i>Journal of Lipid Research</i> , 2014, 55, 2370-2379.	2.0	59
93	Lipid lowering with PCSK9 inhibitors. <i>Nature Reviews Cardiology</i> , 2014, 11, 563-575.	6.1	207
94	Biologics for the Treatment of Dyslipidemias. <i>Annals of Pharmacotherapy</i> , 2014, 48, 238-249.	0.9	2
95	PCSK9 and lipid lowering drugs. <i>Clinica Chimica Acta</i> , 2014, 437, 66-71.	0.5	32
97	Reduction of Low-Density Lipoprotein Cholesterol by Monoclonal Antibody Inhibition of PCSK9. <i>Annual Review of Medicine</i> , 2014, 65, 417-431.	5.0	80
98	LDL cholesterol: controversies and future therapeutic directions. <i>Lancet, The</i> , 2014, 384, 607-617.	6.3	229

#	ARTICLE	IF	CITATIONS
99	Combination therapy in dyslipidemia: Where are we now?. <i>Atherosclerosis</i> , 2014, 237, 319-335.	0.4	39
100	Recent advances in pharmacotherapy for hypertriglyceridemia. <i>Progress in Lipid Research</i> , 2014, 56, 47-66.	5.3	128
101	Non-cardiovascular effects associated with statins. <i>BMJ, The</i> , 2014, 349, g3743-g3743.	3.0	137
102	Targeting PCSK9 for Hypercholesterolemia. <i>Annual Review of Pharmacology and Toxicology</i> , 2014, 54, 273-293.	4.2	96
104	Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies. <i>Cardiovascular Drugs and Therapy</i> , 2014, 28, 281-289.	1.3	86
105	Lipoprotein(a) as a therapeutic target in cardiovascular disease. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 747-757.	1.5	16
106	Investigational therapies for the treatment of atherosclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1411-1421.	1.9	8
107	The Ebbs and Flows in the Development of Cholesterol-Lowering Drugs: Prospects for the Future. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 64-73.	2.3	13
108	Emerging Therapeutic Approaches to Treat Dyslipidemia. <i>Current Cardiology Reports</i> , 2014, 16, 506.	1.3	6
109	Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. <i>Nature Genetics</i> , 2014, 46, 357-363.	9.4	428
110	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>International Journal of Cardiology</i> , 2014, 171, 309-325.	0.8	316
111	Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels. <i>Atherosclerosis</i> , 2014, 233, 123-129.	0.4	39
112	Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. <i>Vascular Pharmacology</i> , 2014, 62, 94-102.	1.0	95
113	Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia. <i>Circulation</i> , 2014, 129, 234-243.	1.6	204
114	Critical review of non-statin treatments for dyslipoproteinemia. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 359-371.	0.6	6
115	Are antibodies against PCSK9 the statins of the 21st century?. <i>Clinical Lipidology</i> , 2014, 9, 141-144.	0.4	0
116	Effects of Evolocumab (AMG 145), a Monoclonal Antibody to PCSK9, in Hypercholesterolemic, Statin-Treated Japanese Patients at High Cardiovascular Risk. <i>Circulation Journal</i> , 2014, 78, 1073-1082.	0.7	97
118	Lipids, blood pressure and kidney update 2015. <i>Lipids in Health and Disease</i> , 2015, 14, 167.	1.2	49

#	ARTICLE	IF	CITATIONS
119	Genetics of coronary heart disease: towards causal mechanisms, novel drug targets and more personalized prevention. <i>Journal of Internal Medicine</i> , 2015, 278, 433-446.	2.7	30
120	PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 590-601.	2.3	4
121	PCSK9 inhibition: the way forward in the treatment of dyslipidemia. <i>BMC Medicine</i> , 2015, 13, 258.	2.3	32
122	â€˜LDL-Câ€™=â€˜LDL-Câ€™+â€˜Lp(a)-C. <i>Current Opinion in Lipidology</i> , 2015, 26, 169-178.	1.2	122
123	Statin intolerance. <i>Current Opinion in Lipidology</i> , 2015, 26, 492-501.	1.2	32
124	Stairs instead of elevators at the workplace decreases <sc>PCSK</sc>9 levels in a healthy population. <i>European Journal of Clinical Investigation</i> , 2015, 45, 1017-1024.	1.7	34
125	Therapeutic Management of Familial Hypercholesterolemia: Current and Emerging Drug Therapies. <i>Pharmacotherapy</i> , 2015, 35, 1189-1203.	1.2	17
126	Potential of PCSK9 as a new target for the management of LDL cholesterol. <i>Research Reports in Clinical Cardiology</i> , 0, , 73.	0.2	6
127	Profile of evolocumab and its potential in the treatment of hyperlipidemia. <i>Drug Design, Development and Therapy</i> , 2015, 9, 3073.	2.0	19
128	Position paper Statin intolerance â€“ an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2015, 1, 1-23.	0.4	311
129	Statin-associated muscle symptoms: impact on statin therapyâ€”European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>European Heart Journal</i> , 2015, 36, 1012-1022.	1.0	1,024
130	Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis. <i>Postgraduate Medicine</i> , 2015, 127, 125-132.	0.9	14
131	New Drugs for Treating Dyslipidemia: Beyond Statins. <i>Diabetes and Metabolism Journal</i> , 2015, 39, 87.	1.8	46
132	PCSK9 Inhibitors and Neurocognitive Adverse Events: Exploring the FDA Directive and a Proposal for N-of-1 Trials. <i>Drug Safety</i> , 2015, 38, 519-526.	1.4	59
133	PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia. <i>European Journal of Pharmacology</i> , 2015, 763, 38-47.	1.7	32
134	Lipid Management in Diabetes with a Focus on Emerging Therapies. <i>Canadian Journal of Diabetes</i> , 2015, 39, S183-S190.	0.4	8
135	Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes. <i>Clinical Therapeutics</i> , 2015, 37, 2751-2769.	1.1	27
136	Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 287-298.	1.4	6

#	ARTICLE	IF	CITATIONS
137	Type 2 Diabetes Mellitus, Metabolic Syndrome, and Mixed Dyslipidemia: How Similar, How Different, and How to Treat?. <i>Metabolic Syndrome and Related Disorders</i> , 2015, 13, 1-21.	0.5	26
138	PCSK9 Inhibition: Current Concepts and Lessons from Human Genetics. <i>Current Atherosclerosis Reports</i> , 2015, 17, 487.	2.0	9
139	Antisense Oligonucleotides, microRNAs, and Antibodies. <i>Handbook of Experimental Pharmacology</i> , 2015, 224, 649-689.	0.9	7
140	Targeting PCSK9 for Therapeutic Gains. <i>Current Atherosclerosis Reports</i> , 2015, 17, 499.	2.0	22
141	Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2638-2651.	1.2	156
142	Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta-Analysis of 20 Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2015, 4, e001937.	1.6	66
143	Novel Lipid-Lowering Agents. <i>Contemporary Endocrinology</i> , 2015, , 499-519.	0.3	0
144	PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a). <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 295-308.	1.3	18
145	Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. <i>Journal of Clinical Lipidology</i> , 2015, 9, 295-304.	0.6	128
146	Screening and treatment of familial hypercholesterolemia – Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014). <i>Atherosclerosis</i> , 2015, 241, 597-606.	0.4	34
147	Statin Intolerance: Diagnosis and Remedies. <i>Current Cardiology Reports</i> , 2015, 17, 27.	1.3	32
148	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia. <i>Annals of Internal Medicine</i> , 2015, 163, 40-51.	2.0	357
149	Evolocumab (AMG 145) for primary hypercholesterolemia. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 477-488.	0.6	50
150	The Promise of Proprotein Convertase Subtilisin/Kexin 9 Inhibitors for the Treatment of Familial Hypercholesterolemia. <i>Current Atherosclerosis Reports</i> , 2015, 17, 508.	2.0	0
151	Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 935-955.	1.0	117
152	Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2015, 372, 1500-1509.	13.9	1,352
153	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 19-31.	1.6	46
154	Update of Clinical Trials of Anti-PCSK9 Antibodies. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 159-169.	1.3	7

#	ARTICLE	IF	CITATIONS
155	PCSK9 antibodies: A new class of lipid-lowering drugs. <i>Atherosclerosis Supplements</i> , 2015, 18, 21-27.	1.2	16
156	Atherosclerosis: Recent trials, new targets and future directions. <i>International Journal of Cardiology</i> , 2015, 192, 72-81.	0.8	28
157	Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). <i>Basic Research in Cardiology</i> , 2015, 110, 4.	2.5	94
158	PCSK9 Inhibitors: The Next Frontier in Low-Density Lipoprotein Lowering. <i>Metabolic Syndrome and Related Disorders</i> , 2015, 13, 99-101.	0.5	3
159	The rs13064411 polymorphism in the WDR52 gene, associated with PCSK9 levels, modifies statin-induced changes in serum total and LDL cholesterol levels. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 134-142.	0.7	6
160	PCSK9 inhibition in patients with hypercholesterolemia. <i>Trends in Cardiovascular Medicine</i> , 2015, 25, 567-574.	2.3	24
161	Characterization of Autosomal Dominant Hypercholesterolemia Caused by <i>PCSK9</i> Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 823-831.	5.1	90
162	Strategies for Improving Cardiovascular Health in Women With Diabetes Mellitus: a Review of the Evidence. <i>Current Diabetes Reports</i> , 2015, 15, 98.	1.7	2
163	Nonstatin Therapies for Management of Dyslipidemia: A Review. <i>Clinical Therapeutics</i> , 2015, 37, 2153-2179.	1.1	39
164	Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition. <i>Circulation</i> , 2015, 132, 1648-1666.	1.6	152
165	Lipoprotein(a). <i>Contemporary Endocrinology</i> , 2015, , 25-55.	0.3	2
166	The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1275-1286.	2.5	50
167	Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. <i>BMC Medicine</i> , 2015, 13, 123.	2.3	200
168	Is there enough evidence with evolocumab and alirocumab (antibodies to proprotein convertase) Tj ETQq1 1 0.784314 rgBT /Overlock <i>Biological Therapy</i> , 2015, 15, 1671-1675.	1.4	12
169	Evolocumab: First Global Approval. <i>Drugs</i> , 2015, 75, 1567-1573.	4.9	16
170	LDL Cholesterol, Statins And PCSK 9 Inhibitors. <i>Indian Heart Journal</i> , 2015, 67, 419-424.	0.2	13
171	Ongoing challenges for pharmacotherapy for dyslipidemia. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 347-356.	0.9	6
172	An epidemiological perspective of personalized medicine: the <i>stonian</i> experience. <i>Journal of Internal Medicine</i> , 2015, 277, 188-200.	2.7	22

#	ARTICLE	IF	CITATIONS
173	Looking into the Crystal Ball – Upcoming Drugs for Dyslipidemia. Journal of Cardiovascular Pharmacology and Therapeutics, 2015, 20, 11-20.	1.0	11
174	PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels. , 2015, 145, 58-66.		44
175	Proprotein Convertase Subtilisin/Kexin 9 Inhibitors. Journal of Cardiovascular Pharmacology and Therapeutics, 2015, 20, 157-168.	1.0	53
176	Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders. Vascular Health and Risk Management, 2016, Volume 12, 421-433.	1.0	8
177	A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 641-653q.	0.5	47
178	Development of Antisense Drugs for Dyslipidemia. Journal of Atherosclerosis and Thrombosis, 2016, 23, 1011-1025.	0.9	15
179	What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management?. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 97-105.	1.2	9
180	Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015). Expert Opinion on Therapeutic Patents, 2016, 26, 1377-1392.	2.4	23
181	PCSK9 inhibitors. Journal of Cardiovascular Medicine, 2016, 17, 237-244.	0.6	5
182	Positive correlation of plasma PCSK9 levels with HbA _{1c} in patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2016, 32, 193-199.	1.7	36
183	Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors. Current Opinion in Cardiology, 2016, 31, 644-653.	0.8	4
184	Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). American Heart Journal, 2016, 176, 83-92.	1.2	45
185	Inhibición de la proproteína convertasa subtilisina/kexina tipo 9 en el tratamiento de la hipercolesterolemia. Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2016, 63, 255-257.	0.8	5
186	Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials. American Heart Journal, 2016, 178, 135-144.	1.2	58
187	Monoclonal Antibodies for Lipid Management. Current Atherosclerosis Reports, 2016, 18, 39.	2.0	6
188	PCSK9 inhibitors in the prevention of cardiovascular disease. Journal of Thrombosis and Thrombolysis, 2016, 42, 405-419.	1.0	26
189	Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance. JAMA - Journal of the American Medical Association, 2016, 315, 1580.	3.8	420
190	Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. Atherosclerosis, 2016, 244, 138-146.	0.4	163

#	ARTICLE	IF	CITATIONS
191	PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab. <i>Future Cardiology</i> , 2016, 12, 139-148.	0.5	5
192	PCSK9 Inhibitors for Statin Intolerance?. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1571.	3.8	16
193	Statin combination therapy and cardiovascular risk reduction. <i>Future Cardiology</i> , 2016, 12, 289-315.	0.5	13
195	Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study. <i>International Journal of Cardiology</i> , 2016, 215, 293-298.	0.8	63
196	Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol. , 2016, 164, 183-194.		20
197	PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. <i>Journal of Lipid Research</i> , 2016, 57, 1086-1096.	2.0	180
198	HIV and Hepatitis Câ€“Coinfected Patients Have Lower Lowâ€“Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent â€œPCSK9â€“Lipid Paradoxâ€• <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	36
199	Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction. <i>American Journal of Cardiology</i> , 2016, 118, 19A-32A.	0.7	8
200	Inhibition of proprotein convertase subtilisin/kexin type 9 in the treatment of hypercholesterolemia. <i>EndocrinologÃa Y NutriciÃ3n (English Edition)</i> , 2016, 63, 255-257.	0.5	3
201	Drugs for hypercholesterolaemia â€“ from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition. <i>Clinical Medicine</i> , 2016, 16, 353-357.	0.8	8
202	Statin Intolerance: A Literature Review and Management Strategies. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 153-164.	1.6	60
203	Cardiovascular Disease, Mortality Risk, and Healthcare Costs by Lipoprotein(a) Levels According to Lowâ€“density Lipoprotein Cholesterol Levels in Older Highâ€“risk Adults. <i>Clinical Cardiology</i> , 2016, 39, 413-420.	0.7	19
204	Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2016, 23, 217-230.	1.0	31
205	Managing the lipid profile of coronary heart disease patients. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 1263-1271.	0.6	8
206	Efficacy and safety of different doses of evolocumab in reducing low-density lipoprotein cholesterol levels: A meta-analysis. <i>Biomedical Reports</i> , 2016, 5, 541-547.	0.9	5
207	Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160Ãmg/dl or Higher. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 473-483.	1.3	160
208	<sc>PCSK</sc>9 in diabetic kidney disease. <i>European Journal of Clinical Investigation</i> , 2016, 46, 779-786.	1.7	21
209	LDL-Cholesterol: Standards of Treatment 2016: A German Perspective. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 323-336.	1.0	18

#	ARTICLE	IF	CITATIONS
210	Monthly PCSK9 inhibitors: The CHOICE for prolonged duration of effect. <i>Atherosclerosis</i> , 2016, 254, 300-302.	0.4	1
211	European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. <i>European Heart Journal</i> , 2017, 38, ehw480.	1.0	137
212	PCSK9: the Critical Role of Familial Hypercholesterolemia from Discovery to Benefit for all. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 427-431.	1.3	5
213	Statins and Their Effect on PCSK9â€™Impact and Clinical Relevance. <i>Current Atherosclerosis Reports</i> , 2016, 18, 46.	2.0	40
214	New agents for hypercholesterolemia. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 172-177.	0.1	1
216	Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 305-313.	1.3	30
217	Expert opinion: the therapeutic challenges faced by statin intolerance. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1497-1507.	0.9	43
218	Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 853-862.	1.1	37
219	Update on PCSK9 therapies for the treatment of dyslipidemia. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 87-95.	1.2	2
220	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). <i>Canadian Journal of Cardiology</i> , 2016, 32, S35-S65.	0.8	194
221	Evolocumab: A Review in Hyperlipidemia. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 67-78.	1.0	9
222	Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence. <i>Translational Research</i> , 2016, 173, 19-29.	2.2	45
223	PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study. <i>Atherosclerosis</i> , 2016, 248, 117-122.	0.4	137
224	New Era of Lipid-Lowering Drugs. <i>Pharmacological Reviews</i> , 2016, 68, 458-475.	7.1	45
225	Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 59-71.	2.3	10
226	Comparison of <sc>PCSK9</sc> Inhibitor Evolocumab vs Ezetimibe in Statinâ€™ntolerant Patients: Design of the Goal Achievement After Utilizing an Antiâ€™<sc>PCSK9</sc> Antibody in Statinâ€™ntolerant Subjects 3 (<sc>GAUSS</sc>â€™3) Trial. <i>Clinical Cardiology</i> , 2016, 39, 137-144.	0.7	32
227	Interventions for Extracranial Carotid Artery Stenosis: An Update. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2016, 18, 34.	0.4	2
228	A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk. <i>American Journal of Cardiology</i> , 2016, 117, 40-47.	0.7	93

#	ARTICLE	IF	CITATIONS
229	Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. <i>American Journal of Clinical Nutrition</i> , 2016, 103, 965-978.	2.2	437
230	Management of residual risk after statin therapy. <i>Atherosclerosis</i> , 2016, 245, 161-170.	0.4	71
231	Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 369-380.	0.9	43
232	The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. <i>European Heart Journal</i> , 2016, 37, 536-545.	1.0	211
233	Statin tolerability: In defence of placebo-controlled trials. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 891-896.	0.8	32
234	Lipoprotein Metabolism and the Treatment of Lipid Disorders. , 2016, , 715-736.e7.		5
236	Hypothesis. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2017, 22, 56-64.	1.0	2
237	Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. <i>Journal of Medical Economics</i> , 2017, 20, 555-564.	1.0	49
238	The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies. <i>Clinical Science</i> , 2017, 131, 261-268.	1.8	34
239	Increased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	51
240	Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab. <i>JAMA Cardiology</i> , 2017, 2, 556.	3.0	22
241	Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. <i>Circulation</i> , 2017, 135, 1819-1831.	1.6	67
242	PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook. <i>BioDrugs</i> , 2017, 31, 167-174.	2.2	14
243	PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?. <i>Heart</i> , 2017, 103, 1670-1679.	1.2	21
244	CAT α 2003: A novel sterol regulatory element α -binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3 α Leiden mice. <i>Hepatology Communications</i> , 2017, 1, 311-325.	2.0	16
245	Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice. <i>Journal of Lipid Research</i> , 2017, 58, 1661-1669.	2.0	41
246	Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials. <i>Scientific Reports</i> , 2017, 7, 238.	1.6	29
247	Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from) <i>Tj ETQq1 1 0.7843144 BT /Over</i>	0.7843144	14

#	ARTICLE	IF	CITATIONS
248	Long-term Low-Density Lipoprotein Cholesterolâ€“Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia. <i>JAMA Cardiology</i> , 2017, 2, 598.	3.0	137
249	Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 1-26.	1.0	45
250	Crosstalk of Hyperglycemia and Dyslipidemia in Diabetic Kidney Disease. <i>Kidney Diseases (Basel)</i> , 2017, 1, 1-10.	1.2	31
251	Trial designs for statin muscle intolerance. <i>Current Opinion in Lipidology</i> , 2017, 28, 488-494.	1.2	5
252	Strategies for the use of nonstatin therapies. <i>Current Opinion in Lipidology</i> , 2017, 28, 458-464.	1.2	2
253	PCSK9 inhibition in statin-intolerant HeFH patients: Whatâ€™s new?. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1525-1527.	0.8	0
254	Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2017, 120, 1521-1527.	0.7	36
255	Evolocumab for the treatment of hypercholesterolemia. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1-15.	1.4	5
256	The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab. <i>Journal of Lipid Research</i> , 2017, 58, 2008-2016.	2.0	26
257	Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	147
259	PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis. <i>Internal and Emergency Medicine</i> , 2017, 12, 1043-1053.	1.0	11
260	PCSK9 Inhibitors: Treating the Right Patients in Daily Practice. <i>Current Cardiology Reports</i> , 2017, 19, 66.	1.3	1
261	Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium. <i>Current Medical Research and Opinion</i> , 2017, 33, 239-251.	0.9	18
262	PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 7-32.	1.0	41
263	Statin intolerance â€“ a question of definition. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 55-63.	1.0	14
264	Optimizing Cholesterol Treatment in Patients With Muscle Complaints. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1290-1301.	1.2	162
265	Thyroid hormones: a potential ally to LDL-cholesterol-lowering agents. <i>Hormones</i> , 2017, 15, 500-510.	0.9	16
266	Identification of candidate protective variants for common diseases and evaluation of their protective potential. <i>BMC Genomics</i> , 2017, 18, 575.	1.2	15

#	ARTICLE	IF	CITATIONS
267	Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up. Drug Design, Development and Therapy, 2017, Volume 11, 2121-2129.	2.0	10
268	PCSK9 inhibitors “ from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade. Archives of Medical Science, 2017, 4, 914-929.	0.4	22
269	PCSK9 inhibitors: A new era of lipid lowering therapy. World Journal of Cardiology, 2017, 9, 76.	0.5	200
270	High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes. Current Cardiology Reviews, 2017, 13, 168-182.	0.6	9
271	Statin Intolerance: Diagnosis and Management. Indian Journal of Cardiovascular Disease in Women WINCARS, 2017, 02, 014-020.	0.1	0
272	Advances in Hypercholesterolemia. , 2017, , 663-693.		1
273	Evolocumab: Considerations for the Management of Hyperlipidemia. Current Atherosclerosis Reports, 2018, 20, 17.	2.0	9
274	The Role of PCSK9 Inhibitors in the Treatment of Hypercholesterolemia. Annals of Pharmacotherapy, 2018, 52, 1000-1018.	0.9	21
275	Real-life achievement of lipid-lowering treatment targets in the DIABetes and LiFEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factors. Nutrition and Diabetes, 2018, 8, 24.	1.5	15
276	Inclisiran for the treatment of dyslipidemia. Expert Opinion on Investigational Drugs, 2018, 27, 287-294.	1.9	40
277	Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clinical Pharmacokinetics, 2018, 57, 769-779.	1.6	81
278	Proprotein Convertase Subtilisin Kexin 9 Inhibitors. Cardiology Clinics, 2018, 36, 241-256.	0.9	5
279	PCSK9 and infection: A potentially useful or dangerous association?. Journal of Cellular Physiology, 2018, 233, 2920-2927.	2.0	26
280	Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin. Cardiovascular Therapeutics, 2018, 36, e12308.	1.1	15
281	PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes. Annual Review of Medicine, 2018, 69, 133-145.	5.0	55
282	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care, 2018, 41, 364-367.	4.3	88
283	Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease. Pharmacoeconomics, 2018, 36, 115-126.	1.7	8
284	Genetic architecture: the shape of the genetic contribution to human traits and disease. Nature Reviews Genetics, 2018, 19, 110-124.	7.7	335

#	ARTICLE	IF	CITATIONS
285	Using Human "Experiments of Nature"™ to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors. <i>Drug Safety</i> , 2018, 41, 303-311.	1.4	22
286	Statin Intolerance: an Overview of the Current Status and Possible Treatment Options. <i>Journal of Lipid and Atherosclerosis</i> , 2018, 7, 77.	1.1	3
287	Large-Scale Phenome-Wide Association Study of <i>PCSK9</i> Variants Demonstrates Protection Against Ischemic Stroke. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002162.	1.6	48
288	Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 365-372.	1.3	19
289	The Evolving Future of PCSK9 Inhibitors. <i>Journal of the American College of Cardiology</i> , 2018, 72, 314-329.	1.2	162
290	Population pharmacokinetics and exposure"response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018, 45, 505-522.	0.8	4
291	Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia?. <i>Drugs</i> , 2018, 78, 799-808.	4.9	15
292	Consistent LDL" response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. <i>Clinical Cardiology</i> , 2018, 41, 1328-1335.	0.7	25
293	PCSK9 in cholesterol metabolism: from bench to bedside. <i>Clinical Science</i> , 2018, 132, 1135-1153.	1.8	28
294	PCSK9 inhibition and inflammation: A narrative review. <i>Atherosclerosis</i> , 2019, 288, 146-155.	0.4	80
295	Guia pr"tico para a utiliza"o dos inibidores da PCSK9 em Portugal. <i>Revista Portuguesa De Cardiologia</i> , 2019, 38, 391-405.	0.2	0
296	Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia. <i>Journal of Lipid Research</i> , 2019, 60, 1610-1621.	2.0	18
297	Association of baseline LDL-C with total and cardiovascular mortality in patients using proprotein convertase subtilisin-kexin type 9 inhibitors: A systematic review and meta-analysis. <i>Journal of Clinical Lipidology</i> , 2019, 13, 538-549.	0.6	16
298	Efficacy and safety of PCSK9 monoclonal antibodies. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 1191-1201.	1.0	16
299	Practical guide for the use of PCSK9 inhibitors in Portugal. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2019, 38, 391-405.	0.2	1
300	Statin Toxicity. <i>Circulation Research</i> , 2019, 124, 328-350.	2.0	439
301	Elevated lipoprotein (a) levels are associated with the acute myocardial infarction in patients with normal low-density lipoprotein cholesterol levels. <i>Bioscience Reports</i> , 2019, 39, .	1.1	14
302	Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis. <i>Heart</i> , 2019, 105, heartjnl-2019-314763.	1.2	20

#	ARTICLE	IF	CITATIONS
303	Latest Updates on Lipid Management. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 85-100.	1.0	5
304	A Meta-Analysis of the Effect of PCSK9-Monoclonal Antibodies on Circulating Lipoprotein (a) Levels. American Journal of Cardiovascular Drugs, 2019, 19, 87-97.	1.0	38
305	Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs. American Journal of Cardiovascular Drugs, 2019, 19, 113-131.	1.0	4
306	Inhibiting PCSK9 " biology beyond LDL control. Nature Reviews Endocrinology, 2019, 15, 52-62.	4.3	96
307	PCSK9: from biology to clinical applications. Pathology, 2019, 51, 177-183.	0.3	29
308	Real-world use of PCSK9 inhibitors: A single-center experience. Journal of International Medical Research, 2019, 47, 265-270.	0.4	9
309	Critical review of 2016 ACC guidelines on therapies for cholesterol lowering with reference to laboratory testing. Clinica Chimica Acta, 2019, 489, 189-195.	0.5	4
310	Integrative analysis of rare copy number variants and gene expression data in alopecia areata implicates an aetiological role for autophagy. Experimental Dermatology, 2020, 29, 243-253.	1.4	21
311	Statin Intolerance" An Asian Perspective. Journal of Atherosclerosis and Thrombosis, 2020, 27, 485-488.	0.9	9
312	Non"High-Density Lipoprotein Cholesterol and Guidelines for Cholesterol Lowering in Recent History. Laboratory Medicine, 2020, 51, 14-23.	0.8	10
313	Genetics"™ Piece of the PI: Inferring the Origin of Complex Traits and Diseases from Proteome"Wide Protein"Protein Interaction Dynamics. BioEssays, 2020, 42, 1900169.	1.2	0
314	Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial. Journal of Atherosclerosis and Thrombosis, 2020, 27, 471-484.	0.9	14
315	An update on PCSK9 inhibitors- pharmacokinetics, drug interactions, and toxicity. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 1199-1205.	1.5	10
316	Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol. American Journal of Preventive Cardiology, 2020, 1, 100012.	1.3	13
317	Progress and prospects of biological approaches targeting PCSK9 for cholesterol-lowering, from molecular mechanism to clinical efficacy. Expert Opinion on Biological Therapy, 2020, 20, 1477-1489.	1.4	2
318	Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update. Journal of Drug Assessment, 2020, 9, 129-144.	1.1	17
319	PCSK9 in African Americans and Caucasians in Relation to Lp(a) Level, Apo(a) Size and Heritability. Journal of the Endocrine Society, 2020, 4, bvaa073.	0.1	6
320	Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes. Cardiovascular Diabetology, 2020, 19, 33.	2.7	26

#	ARTICLE	IF	CITATIONS
321	Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 787-796.	1.3	19
322	Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2020, 155, 104719.	3.1	17
323	Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 403-414.	2.5	3
324	LDL-Cholesterol-Lowering Therapy. <i>Handbook of Experimental Pharmacology</i> , 2020, , 1.	0.9	8
325	Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 225-235.	1.4	40
326	Biotechnology Approaches for the Treatment of Dyslipidemia. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 167-183.	1.3	4
327	Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 33-43.	0.8	33
328	Effects of Evolocumab on Low-Density Lipoprotein Cholesterol, Non-High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta-Analysis of Individual Participant Data From Double-Blind and Open-Label Extension Studies. <i>Journal of the American Heart Association</i> , 2021, 10, e016839.	1.6	14
329	PCSK9 Antibody-based Treatment Strategies for Patients With Statin Intolerance. <i>In Vivo</i> , 2021, 35, 61-68.	0.6	5
330	Lipoprotein(a) Reduction With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 397-407.	0.8	29
331	Three Musketeers for Lowering Cholesterol: Statins, Ezetimibe and Evolocumab. <i>Current Medicinal Chemistry</i> , 2021, 28, 1025-1041.	1.2	10
332	Effectiveness, Safety, and Adherence to Treatment of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Real Practice. <i>Clinical Therapeutics</i> , 2021, 43, e111-e121.	1.1	6
333	High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2660-2670.	1.4	7
334	Proprotein convertase subtilisin/kexin type 9 inhibition as the next statin?. <i>Current Opinion in Lipidology</i> , 2020, 31, 340-346.	1.2	6
336	Statin non-adherence: clinical consequences and proposed solutions. <i>F1000Research</i> , 2016, 5, 714.	0.8	11
337	Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors. <i>Journal of Lipid and Atherosclerosis</i> , 2019, 8, 183.	1.1	16
338	The Emerging Role of PCSK9 Inhibitors in Preventive Cardiology. <i>European Cardiology Review</i> , 2014, 9, 65.	0.7	6
339	Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors. <i>Current Medicinal Chemistry</i> , 2020, 27, 4494-4521.	1.2	1

#	ARTICLE	IF	CITATIONS
340	Hypolipidaemic Drug Treatment: Yesterday is Not Gone Yet, Today is Challenging and Tomorrow is Coming Soon; let us Combine them all. <i>Current Pharmaceutical Design</i> , 2014, 20, 6350-6357.	0.9	9
341	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease. <i>Current Drug Metabolism</i> , 2019, 20, 72-82.	0.7	12
342	PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol. <i>Mini-Reviews in Medicinal Chemistry</i> , 2018, 19, 165-176.	1.1	26
343	A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 1790-1817.	1.0	13
344	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. <i>Current Vascular Pharmacology</i> , 2019, 17, 515-537.	0.8	19
345	PCSK9 Inhibitors and Cardiovascular Disease: Impact on Cardiovascular Outcomes. <i>Current Drug Discovery Technologies</i> , 2020, 17, 138-146.	0.6	5
346	Advances in the treatment of dyslipidemia. <i>Cleveland Clinic Journal of Medicine</i> , 2016, 83, 181-186.	0.6	12
347	The Lausanne Institutional Biobank: A new resource to catalyse research in personalised medicine and pharmaceutical sciences. <i>Swiss Medical Weekly</i> , 2014, 144, w14033.	0.8	14
348	PCSK9 and triglyceride-rich lipoprotein metabolism. <i>Journal of Biomedical Research</i> , 2015, 29, 429.	0.7	29
349	Efficacy and Safety of Lipid-Lowering Drugs of Different Intensity on Clinical Outcomes: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 713007.	1.6	6
350	PCSK9 - A New and Potent Approach to Lowering Cholesterol. <i>Oman Medical Journal</i> , 2013, 28, 155-158.	0.3	0
352	PCSK9 and LDLR The Yin-Yang in the Cellular Uptake of Cholesterol. <i>Current Hypertension Reviews</i> , 2014, 9, 310-323.	0.5	3
353	Limitaciones más frecuentes en los ensayos clínicos con Asignación Aleatoria (ECA) en el Área de medicina interna. <i>Revista Med</i> , 2015, 23, 35.	0.1	2
354	Use and role of monoclonal antibodies and other biologics in preventive cardiology. <i>Swiss Medical Weekly</i> , 2015, 145, w14179.	0.8	3
355	Update on PCSK9 Inhibitors and New Therapies. <i>US Endocrinology</i> , 2016, 12, 18.	0.3	1
357	Whole-Exomes Sequencing Delineates Gene Variants Profile in a Young Saudi Male with Familial Hypercholesterolemia: Case Report. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2017, 11, GD01-GD06.	0.8	3
359	Novel lipid-lowering agents proprotein convertase subtilisin-kexin type 9 inhibitors: Do they show mortality benefits?. <i>International Journal of Applied & Basic Medical Research</i> , 2018, 8, 135.	0.2	0
361	PCSK9 Inhibition with Evolocumab Reaching Physiologic LDL-C Levels for Reducing Atherosclerotic Burden and Cardiovascular Disease-The Full Landscape. <i>Frontiers in Cardiovascular Drug Discovery</i> , 2019, , 148-185.	0.0	0

#	ARTICLE	IF	CITATIONS
362	Large Clinical Trials of Statin-Associated Muscle Symptoms. <i>Contemporary Cardiology</i> , 2020, , 63-70.	0.0	0
363	Management of Statin Intolerance. <i>Contemporary Cardiology</i> , 2021, , 207-218.	0.0	0
364	Efficacy of Evolocumab in Patients with Hypercholesterolemia. <i>Kosin Medical Journal</i> , 2020, 35, 125-132.	0.1	1
365	Modern Lipid Management: A Literature Review. <i>Cureus</i> , 2020, 12, e9375.	0.2	1
366	A safety and clinical efficacy analysis of PCSK9 monoclonal antibodies in patients with markedly elevated creatine phosphokinase levels. <i>American Journal of Blood Research</i> , 2021, 11, 399-404.	0.6	0
367	Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 789931.	1.1	32
368	Bayesian model comparison for rare-variant association studies. <i>American Journal of Human Genetics</i> , 2021, 108, 2354-2367.	2.6	2
369	Novel therapeutic targets and agents for pediatric dyslipidemia. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882110583.	1.4	4
370	Contemporary Management of Dyslipidemia. <i>Drugs</i> , 2022, 82, 559-576.	4.9	14
371	The biological relevance of PCSK9: when less is better. <i>Biochemistry and Cell Biology</i> , 2022, 100, 189-198.	0.9	4
372	Chemiluminescent screening of specific hybridoma cells via a proximity-rolling circle activated enzymatic switch. <i>Communications Biology</i> , 2022, 5, 308.	2.0	2
373	Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. <i>Journal of Clinical Lipidology</i> , 2022, 16, 538-543.	0.6	4
374	SAMSON and the Nocebo Effect: Management of Statin Intolerance. <i>Current Cardiology Reports</i> , 2022, 24, 1101-1108.	1.3	9
375	The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs. , 2022, 1, 2-13.		0
376	Cholesterol-lowering drugs: Focus on Ezetimibe: Cholesterol-lowering drugs: Focus on ezetimibe. , 2022, 1, 14-24.		0
377	Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	12
378	Low density lipoprotein receptor endocytosis in cardiovascular disease and the factors affecting LDL levels. <i>Progress in Molecular Biology and Translational Science</i> , 2023, , 333-345.	0.9	2
379	Diaporisoindole B Reduces Lipid Accumulation in THP-1 Macrophage Cells via MAPKs and PPAR γ -LXR β Pathways and Promotes the Reverse Cholesterol Transport by Upregulating SR-B1 and LDLR in HepG2 Cells. <i>Journal of Natural Products</i> , 2022, 85, 2769-2778.	1.5	4

#	ARTICLE	IF	CITATIONS
380	Update on management of paediatric dyslipidaemia. Current Opinion in Endocrinology, Diabetes and Obesity, 2023, 30, 52-64.	1.2	2
381	Low-density lipoprotein-cholesterol lowering effect of a nutraceutical regimen with or without ezetimibe in hypercholesterolaemic patients with statin intolerance. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
382	Is a PCSK9 Inhibitor Right for Your Patient? A Review of Treatment Data for Individualized Therapy. International Journal of Environmental Research and Public Health, 2022, 19, 16899.	1.2	1
383	An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors. Cardiovascular Therapeutics, 2023, 2023, 1-11.	1.1	8
384	Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents. Frontiers in Clinical Drug Research Diabetes and Obesity, 2023, , 117-167.	0.1	0
385	Statin Intolerance: A Review and Update. Endocrine Practice, 2023, , .	1.1	2
386	Effect of Different Types and Dosages of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a) Levels: A Network Meta-analysis. Journal of Cardiovascular Pharmacology, 2023, 81, 445-453.	0.8	7
387	Value of the clinical pharmacist interventions in the application of the American College of Cardiology (ACC/AHA) 2018 guideline for cholesterol management. PLoS ONE, 2023, 18, e0283369.	1.1	0
388	PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease. Current Pharmaceutical Design, 2023, 29, 1802-1824.	0.9	4
393	Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside. Signal Transduction and Targeted Therapy, 2024, 9, .	7.1	1